BioVie (BIVI)
(Delayed Data from NSDQ)
$2.54 USD
+0.05 (2.01%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $2.75 +0.21 (8.27%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.54 USD
+0.05 (2.01%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $2.75 +0.21 (8.27%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Bears are Losing Control Over BioVie Inc. (BIVI), Here's Why It's a 'Buy' Now
by Zacks Equity Research
BioVie Inc. (BIVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
BioVie Inc. (BIVI) Loses -46.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for BioVie Inc. (BIVI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie
by Zacks Equity Research
Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie are included in this Analyst Blog.
Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & More
by Zacks Equity Research
Regulatory and pipeline updates from Avidity Biosciences, Inc. (RNA) and BioVie (BIVI) are in the spotlight this week.
BioVie (BIVI) Falls 61% Despite Upbeat Alzheimer's Study Data
by Zacks Equity Research
BioVie (BIVI) stock plunges 61% in spite of positive phase III Alzheimer's Disease study results due to significant study conduct violations and protocol deviations reported by the company.
Best Momentum Stocks to Buy for October 19th
by Zacks Equity Research
NU, MTRX and BIVI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 19, 2023.
New Strong Buy Stocks for October 19th
by Zacks Equity Research
INTA, NU, ENLV, VCEL and BIVI have been added to the Zacks Rank #1 (Strong Buy) List on October 19, 2023.
Down -26.93% in 4 Weeks, Here's Why BioVie Inc. (BIVI) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for BioVie Inc. (BIVI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Down -29.2% in 4 Weeks, Here's Why You Should You Buy the Dip in BioVie Inc. (BIVI)
by Zacks Equity Research
BioVie Inc. (BIVI) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down -23.45% in 4 Weeks, Here's Why You Should You Buy the Dip in BioVie Inc. (BIVI)
by Zacks Equity Research
The heavy selling pressure might have exhausted for BioVie Inc. (BIVI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Beat the Market Like Zacks: JPMorgan Chase, Oracle, BioVie in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Does BioVie Inc. (BIVI) Have the Potential to Rally 52% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 52.1% in BioVie Inc. (BIVI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here's Why Momentum in BioVie Inc. (BIVI) Should Keep going
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, BioVie Inc. (BIVI) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Are Medical Stocks Lagging BioVie (BIVI) This Year?
by Zacks Equity Research
Here is how BioVie Inc. (BIVI) and Immunovant, Inc. (IMVT) have performed compared to their sector so far this year.
Here's What Could Help BioVie Inc. (BIVI) Maintain Its Recent Price Strength
by Zacks Equity Research
BioVie Inc. (BIVI) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Wall Street Analysts Think BioVie Inc. (BIVI) Could Surge 84%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for BioVie Inc. (BIVI) points to an 84% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is BioVie (BIVI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how BioVie Inc. (BIVI) and Immunovant, Inc. (IMVT) have performed compared to their sector so far this year.
Has Biocept, Inc. (BIOC) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Biocept, Inc. (BIOC) and BioVie Inc. (BIVI) have performed compared to their sector so far this year.
Moving Average Crossover Alert: BioVie (BIVI)
by Zacks Equity Research
BioVie (BIVI) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front